What is the recommended management for thrombocytosis?

Management of Thrombocytosis

The management of thrombocytosis depends critically on distinguishing between secondary (reactive) and primary causes, with treatment directed at the underlying condition for secondary thrombocytosis and risk-stratified cytoreduction for primary thrombocytosis, particularly essential thrombocythemia.

Initial Diagnostic Approach

When thrombocytosis (platelet count ≥450 × 10³/μL) is identified, confirm with a repeat complete blood count with differential and peripheral blood smear 1. The vast majority (98%) of cases are secondary thrombocytosis 2, most commonly due to:

• Infections and inflammatory conditions (most common)
• Iron deficiency
• Acute hemorrhage or hemolysis
• Malignancy
• Tissue damage or surgery
• Medications

Key distinction: Secondary thrombocytosis resolves with treatment of the underlying condition and rarely causes thrombotic complications 3, 2.

When to Suspect Primary Thrombocytosis

Consider essential thrombocythemia (ET) or other myeloproliferative neoplasms when:

• Persistent thrombocytosis without identifiable secondary cause
• Accompanying symptoms: microvascular disturbances (headaches, paresthesias, erythromelalgia), splenomegaly, unexplained thrombosis or hemorrhage 1
• Abnormalities in other cell lines suggesting myeloproliferative disease

Diagnostic Workup for Suspected Primary Thrombocytosis

1. C-reactive protein and ferritin levels to exclude inflammation and iron deficiency 1
2. JAK2 V617F mutation testing (present in ~60% of ET) 4
3. If JAK2 negative: CALR and MPL mutation testing (CALR in ~25%, MPL in ~3%) 4
4. Bone marrow biopsy to confirm diagnosis and exclude prefibrotic myelofibrosis and other myeloid neoplasms 1, 4

Risk Stratification for Essential Thrombocythemia

Use the revised International Prognostic Score of Thrombosis for Essential Thrombocythemia (IPSET-thrombosis) 5, 1:

Risk Categories:

• Very low-risk: Age ≤60 years, no JAK2 mutation, no prior thrombosis
• Low-risk: Age ≤60 years, JAK2 mutation present, no prior thrombosis
• Intermediate-risk: Age >60 years, no JAK2 mutation, no prior thrombosis
• High-risk: Prior thrombosis OR (age >60 years AND JAK2 mutation) 5, 4

Critical caveat: Extreme thrombocytosis (platelets >1,000-1,500 × 10⁹/L) is paradoxically associated with bleeding risk, not thrombosis risk 5, 6, 7.

Treatment Algorithm

For Secondary Thrombocytosis:

Treat the underlying condition only 1, 3. No specific platelet-directed therapy is needed. Thrombotic events in secondary thrombocytosis occur only when additional risk factors are present (e.g., central venous lines, immobility) 2.

For Essential Thrombocythemia:

Very Low-Risk and Low-Risk Disease:

• Observation alone OR low-dose aspirin 81-100 mg daily 5, 4
• Aspirin is recommended for microvascular symptoms (headaches, erythromelalgia, paresthesias) 5, 8
• No cytoreductive therapy unless symptomatic progression occurs 5, 9

Important exception: Use aspirin cautiously if platelet count >1,500 × 10⁹/L due to acquired von Willebrand disease and bleeding risk 5, 6.

Intermediate-Risk Disease:

• Low-dose aspirin 81-100 mg daily 5
• Consider cytoreductive therapy if additional features present:
  • Progressive splenomegaly
  • Symptomatic thrombocytosis
  • Progressive leukocytosis
  • Vasomotor symptoms unresponsive to aspirin 5

High-Risk Disease:

Cytoreductive therapy is mandatory 5, 9, 8:

First-line options:

• Hydroxyurea (starting dose 500 mg twice daily) - preferred at any age 6, 8, 1, 4
• Pegylated interferon-α - preferred in patients <40 years old due to theoretical leukemogenic concerns with hydroxyurea, and in women of childbearing age 6, 8, 4

PLUS low-dose aspirin unless contraindicated 8

Second-line options (for hydroxyurea intolerance/resistance):

• Anagrelide 10, 8, 4
• Busulfan (for elderly with short life expectancy) 6, 8

Special Situations

Symptomatic Thrombocytosis in CML or Other Contexts:

Treatment options include hydroxyurea, anti-aggregants, anagrelide, or apheresis 10. Consider patient age, thromboembolic risk factors, and degree of thrombocytosis when choosing therapy 10.

Extreme Thrombocytosis (>1,500 × 10⁹/L):

• Withhold or use aspirin cautiously due to acquired von Willebrand disease 5, 6
• Initiate cytoreductive therapy regardless of other risk factors 8, 4
• Consider platelet apheresis for acute symptomatic cases 10

Cardiovascular Risk Factor Management

Aggressively manage all cardiovascular risk factors in all patients with ET 9, 8, 1:

• Smoking cessation (mandatory)
• Hypertension control
• Diabetes management
• Hyperlipidemia treatment

Monitoring and Follow-up

• No routine bone marrow monitoring for response assessment 8
• Monitor complete blood counts to maintain platelet count <400-450 × 10⁹/L on cytoreductive therapy 8
• Bone marrow biopsy only indicated if suspecting transformation to myelofibrosis or acute leukemia 8

Common Pitfalls to Avoid

1. Do not treat secondary thrombocytosis with cytoreductive therapy - address the underlying cause only
2. Do not use aspirin in extreme thrombocytosis (>1,500 × 10⁹/L) without first lowering platelet count due to bleeding risk
3. Do not assume elevated platelet count alone increases thrombosis risk - age and prior thrombosis are the dominant risk factors 5, 7
4. Do not use multiple sequential cytotoxic agents - this significantly increases leukemic transformation risk 8